![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
1. Corvert
2. Ibutilide
3. Ibutilide, (+)-isomer
4. Ibutilide, (+-)-isomer
5. Ibutilide, (-)-isomer
6. Ibutilide, Fumarate Salt (2:1), (+)-isomer
7. Ibutilide, Fumarate Salt (2:1), (+-)-isomer
8. N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide
9. U-70226e
10. U-82208e
11. U-82209e
12. U82208e
13. U82209e
1. 122647-32-9
2. Corvert
3. Ibutilide Hemifumarate
4. Ibutilide Fumarate [usan]
5. Ibutilide Hemifumarate Salt
6. U-70226e
7. 9l5x4m5l6i
8. U70226e
9. (e)-but-2-enedioic Acid;n-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
10. N-(4-(4-(ethyl(heptyl)amino)-1-hydroxybutyl)phenyl)methanesulfonamide Hemifumarate
11. 1807940-66-4
12. Ncgc00181771-01
13. Unii-9l5x4m5l6i
14. U 70226e
15. Corvert Fumarate
16. Hsdb 7926
17. Corvert (tn)
18. Mfcd01715410
19. Ibutilide Fumarate (usp)
20. (+-)-4'-(4-(ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (e)-2-butenedioate (2:1)
21. (+-)-4'-(4-(ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide Fumarate (2:1) (salt)
22. (+-)-n-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (e)-butenedioate
23. Dsstox_cid_28578
24. Dsstox_rid_82849
25. Dsstox_gsid_48652
26. Schembl42073
27. Chebi:5857
28. Ibutilide Fumarate [mi]
29. Chembl2355456
30. Dtxsid8048652
31. Hms3714i11
32. Hms3884n07
33. Ibutilide Fumarate [vandf]
34. Ibutilide Fumarate [mart.]
35. Bcp13494
36. Ibutilide Fumarate [usp-rs]
37. Ibutilide Fumarate [who-dd]
38. Tox21_113006
39. S2118
40. Akos015896070
41. Ccg-220685
42. Ibutilide Fumarate [orange Book]
43. As-15378
44. Ibutilide Fumarate [usp Monograph]
45. Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (e)-2-butenedioate (2:1) (salt)
46. Cas-122647-32-9
47. Ibutilide Hemifumarate Salt, >=98% (hplc)
48. Sw220114-1
49. D00648
50. 647i329
51. A804940
52. Q27272695
53. (+/-)-n-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide Hemifumarate
54. Bis(n-(4-(4-(ethyl(heptyl)amino)-1-hydroxybutyl)phenyl)methanesulfonamide) Fumarate
55. (+/-)-4'-(4-(ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide Fumarate (2:1) (salt)
56. Bis(n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide), But-2-enedioic Acid
57. Bis(n-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide),but-2-enedioicacid
58. Ibutilide Fumarate, United States Pharmacopeia (usp) Reference Standard, Monograph Mol Wt. 885.23 ([(c20h36n2o3s)2 . C4h4o4])
59. Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+/-)-, (e)-2-butenedioate (2:1) (salt)
60. N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (e)-2-butenedioate (2:1 Salt)
Molecular Weight | 885.2 g/mol |
---|---|
Molecular Formula | C44H76N4O10S2 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 30 |
Exact Mass | 884.50028698 g/mol |
Monoisotopic Mass | 884.50028698 g/mol |
Topological Polar Surface Area | 231 Ų |
Heavy Atom Count | 60 |
Formal Charge | 0 |
Complexity | 561 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Corvert |
Drug Label | CORVERT Injection (ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties according to the Vaughan Williams Classification. Each milliliter of CORVERT Injection contains... |
Active Ingredient | Ibutilide fumarate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.1mg/ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
2 of 4 | |
---|---|
Drug Name | Ibutilide fumarate |
PubMed Health | Ibutilide (Injection) |
Drug Classes | Antiarrhythmic, Group III |
Drug Label | CORVERT Injection (ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties according to the Vaughan Williams Classification. Each milliliter of CORVERT Injection contains... |
Active Ingredient | Ibutilide fumarate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.1mg/ml |
Market Status | Prescription |
Company | Mylan Institutional; Luitpold |
3 of 4 | |
---|---|
Drug Name | Corvert |
Drug Label | CORVERT Injection (ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties according to the Vaughan Williams Classification. Each milliliter of CORVERT Injection contains... |
Active Ingredient | Ibutilide fumarate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.1mg/ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
4 of 4 | |
---|---|
Drug Name | Ibutilide fumarate |
PubMed Health | Ibutilide (Injection) |
Drug Classes | Antiarrhythmic, Group III |
Drug Label | CORVERT Injection (ibutilide fumarate injection) is an antiarrhythmic drug with predominantly class III (cardiac action potential prolongation) properties according to the Vaughan Williams Classification. Each milliliter of CORVERT Injection contains... |
Active Ingredient | Ibutilide fumarate |
Dosage Form | Injectable |
Route | Injection |
Strength | 0.1mg/ml |
Market Status | Prescription |
Company | Mylan Institutional; Luitpold |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)